U.S. Ties Gavi Funding to Removal of Thimerosal in Vaccines

The Trump administration has asked global vaccine alliance Gavi to phase out vaccines containing the preservative thimerosal as a condition for continued U.S. funding, according to a U.S. health official and a Gavi spokesperson. The request marks a significant move by Washington to influence international immunization policy, particularly in low- and middle-income countries where thimerosal-containing multi-dose vials are widely used. U.S. officials said future funding — including previously pledged amounts — would be withheld until Gavi develops and initiates a plan to remove such vaccines from its portfolio.

Thimerosal, a mercury-based preservative used to maintain vaccine stability in multi-dose vials, has long been targeted by anti-vaccine groups that claim links to autism and neurodevelopmental disorders. However, major health bodies including the World Health Organization (WHO) have repeatedly stated that extensive research over decades has found no credible evidence of harm. While high-income nations have largely shifted to single-dose vaccines where thimerosal use is minimal, global health agencies stress that multi-dose formats remain crucial for cost-effective immunization campaigns in resource-limited settings.

Gavi confirmed it had received the U.S. request and said any change to its vaccine portfolio would require board approval and be guided by scientific consensus. The funding dispute comes amid broader U.S. cuts to international health spending and a policy shift toward bilateral health agreements under an “America First” framework. The U.S. previously provided around 13% of Gavi’s funding, and the alliance has begun cost-cutting measures to address financial gaps as it continues discussions with Washington over future support.

Pic Courtesy: google/ images are subject to copyright